Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  COMPANY NEWS
Company News      
Natco Pharma Ltd.
Change Company   
BSE Code 524816
ISIN Demat INE987B01026
Book Value 467.76
NSE Code NATCOPHARM
Dividend Yield % 0.64
Market Cap 169428.98
P/E 11.30
EPS 83.75
Face Value 2  
20-Mar-2026 NATCO Pharma informs about press release
06-Mar-2026 NATCO Pharma informs about analyst meet
04-Mar-2026 Natco Pharma launches Pomalidomide capsules with ...
04-Mar-2026 Natco Pharma rises on launching Pomalidomide caps...
25-Feb-2026 Natco Pharma informs about clarification on volum...
25-Feb-2026 Clarification sought from Natco Pharma Ltd
24-Feb-2026 Clarification sought from Natco Pharma Ltd
16-Feb-2026 Natco Pharma jumps on getting CDSCO’s approval fo...
14-Feb-2026 Natco Pharma gets CDSCO’s approval for Semaglutid...
13-Feb-2026 Natco Pharma gets EIR for API division in Chennai
13-Feb-2026 NATCO Pharma informs about press release
12-Feb-2026 Natco Pharma gets nod to incorporate wholly owned...
12-Feb-2026 Natco Pharma reports 14% rise in Q3 consolidated ...
12-Feb-2026 Natco Pharma informs about un-audited financial r...
03-Feb-2026 NATCO Pharma gets USFDA's tentative approval for ...
Page 1 of 3
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.